Speaker Profile
Ph.D., PHARMD, BCPS, FCCP, Clinical Pharmacogenetics Implementation Consortium (CPIC), Co-PI and Director, St. Jude
Biography
Kelly E. Caudle, Pharm.D., Ph.D., BCPS, FCCP is the Clinical Pharmacogenetics Implementation Consortium (CPIC) Principal Investigator and Director. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. To date, CPIC has published 26 genebased clinical guidelines covering 25 genes and over 100 drugs. Dr. Caudle oversees all CPICrelated projects and the CPIC guideline development process including the coordination of the guideline writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement. Furthermore, Dr. Caudle is involved in the clinical implementation of pharmacogenetics at St. Jude Childrens Research Hospital. Dr. Caudle received her Pharm.D. and Ph.D. from The University of Tennessee Health Science Center and completed an ASHPaccredited PGY2 residency at Le Bonheur Childrens Hospital. She is also a boardcertified Pharmacotherapy Specialist. Dr. Caudle is currently an affiliate Assistant Professor at The University of Tennessee Health Science Center.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair:
Kelly E. Caudle, St. Jude
The PMWC 2024 Pharmacogenomics (PGx) Track focuses on advancing standardization in pharmacogenomics to achieve better clinical outcomes. The importance of standardization in PGx cannot be overstated as it can help to improve patient care in several ways. Standardization of clinical laboratory processes can help ensure consistent and accurate test results, which is crucial for making informed clinical decisions. Standardization of reporting can help to ensure that test results are communicated in a clear and understandable manner to clinicians and patients. Standardization of pharmacogenomic test ordering and reimbursement can help to ensure that patients have access to the tests they need, regardless of their location or financial situation. Standardization of PGx education can help to ensure that healthcare professionals have the knowledge and skills they need to use PGx in clinical practice effectively. Finally, clinical pearls and outcome data can help to demonstrate the value of PGx in improving patient outcomes and informing clinical decision-making.
- PMWC 2024 PGx Award Ceremony:
Pioneer Honoree: Russ Altman, Stanford
Pioneer Honoree: Andrea Gaedigk, University of Kansas
Luminary Honoree: Teri E. Klein, Stanford - Standardization: Key to Advancing Precision Medicine
Opening Talk: Kelly E. Caudle, St. Jude
- Current and Desired States of Standardization of Clinical Laboratory Processes
Chair: Andrea Gaedigk, University of Kansas
- Vicky Pratt, Agena Bioscience
- FIRESIDE CHAT
Chair: Damon Hostin, Illumina
- Howard McLeod, Utah Tech University
- Current and Desired States of Standardization of Reporting
Chair: Chad Bousman, University of Calgary
- Vicky Pratt, Agena Bioscience
- Lisa Brown
- Susanne Haga, Duke - Current and Desired States of Standardization of Pharmacogenomic Test Ordering and Reimbursement (PANEL)
Chair: Sara Rogers, American Society of Pharmacovigilance
- Jai Patel, Atrium Health
- Greg Warren, Axene Health Partners - Current and Desired State of PGx Education
Chair: Phil Empey, University of Pittsburgh
- Teri E. Klein, Stanford
- Current and Desired State of the Patient Experience in Precision Medicine (PANEL)
Chair: Avni Santani, LetsGetChecked
- Kristy Crooks, University of Colorado - Stuart Scott, Stanford - Clinical Pearls and Outcome Data: Advancing the Adoption of Pharmacogenomics in Clinical Practice
Chair: Kelly E. Caudle, St. Jude
- Larisa H Cavallari, University of Florida
- Jeff Bishop, University of Minnesota - PMWC Showcase
- Bani Tamraz, UCSF
